These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 37727983)

  • 1. Sample size optimization for clinical trials using graphical approaches for multiplicity adjustment.
    Zhang F; Gou J
    Stat Med; 2023 Dec; 42(28):5229-5246. PubMed ID: 37727983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive clinical trial designs with blinded selection of binary composite endpoints and sample size reassessment.
    Roig MB; Melis GG; Posch M; Koenig F
    Biostatistics; 2023 Dec; 25(1):237-252. PubMed ID: 36150142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing unnecessary measurements in clinical trials with multiple primary endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2016; 26(4):631-43. PubMed ID: 26098617
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A case study of an adaptive design for a clinical trial with 2 doses and 2 endpoints in a rare disease area.
    Quan H; Xu Y; Chen Y; Gao L; Chen X
    Pharm Stat; 2018 Nov; 17(6):797-810. PubMed ID: 30221446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new approach for sizing trials with composite binary endpoints using anticipated marginal values and accounting for the correlation between components.
    Bofill Roig M; Gómez Melis G
    Stat Med; 2019 May; 38(11):1935-1956. PubMed ID: 30637797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Simplification or simulation: Power calculation in clinical trials.
    Huang C; Li P; Martin CR
    Contemp Clin Trials; 2022 Feb; 113():106663. PubMed ID: 34958933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of general multistage gatekeeping and graphical multiple testing strategies in a clinical trial setting.
    Li Y; Wang X; Wang D; Offen W
    Contemp Clin Trials; 2019 Jan; 76():9-15. PubMed ID: 30343046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A generalized concept of power helped to choose optimal endpoints in clinical trials.
    Borm GF; van der Wilt GJ; Kremer JA; Zielhuis GA
    J Clin Epidemiol; 2007 Apr; 60(4):375-81. PubMed ID: 17346612
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing clinical trials with (restricted) mean survival time endpoint: Practical considerations.
    Eaton A; Therneau T; Le-Rademacher J
    Clin Trials; 2020 Jun; 17(3):285-294. PubMed ID: 32063031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency of study designs in diagnostic randomized clinical trials.
    Lu B; Gatsonis C
    Stat Med; 2013 Apr; 32(9):1451-66. PubMed ID: 23071073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blinded sample size recalculation in clinical trials with binary composite endpoints.
    Sander A; Rauch G; Kieser M
    J Biopharm Stat; 2017; 27(4):705-715. PubMed ID: 27295402
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple-arm superiority and non-inferiority designs with various endpoints.
    Chang M
    Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.
    Sozu T; Sugimoto T; Hamasaki T
    Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
    Xiong C; Yu K; Gao F; Yan Y; Zhang Z
    Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Some design considerations incorporating early futility for single-arm clinical trials with time-to-event primary endpoints using Weibull distribution.
    Waleed M; He J; Phadnis MA
    Pharm Stat; 2021 May; 20(3):610-644. PubMed ID: 33565236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size determination for a binary response in a superiority clinical trial using a hybrid classical and Bayesian procedure.
    Ciarleglio MM; Arendt CD
    Trials; 2017 Feb; 18(1):83. PubMed ID: 28231813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sample size optimization and initial allocation of the significance levels in group sequential trials with multiple endpoints.
    Gou J
    Biom J; 2022 Feb; 64(2):301-311. PubMed ID: 33751645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.